应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
GUTS Fractyl Health
盘后交易 04-14 16:14:49 EDT
0.5087
+0.0187
+3.82%
盘后
0.5100
+0.0013
+0.26%
16:12 EDT
最高
0.5159
最低
0.4778
成交量
167.66万
今开
0.4778
昨收
0.4900
日振幅
7.78%
总市值
8,070万
流通市值
6,511万
总股本
1.59亿
成交额
84.03万
换手率
1.31%
流通股本
1.28亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
资讯
新帖
简况
Fractyl Health将于2026年3月24日公布2025年第四季度及全年财务业绩并更新业务进展
美股速递 · 03-17
Fractyl Health将于2026年3月24日公布2025年第四季度及全年财务业绩并更新业务进展
Fractyl Health完成Revita®用于GLP-1治疗后体重维持的REMAIN-1关键队列随机分组
美股速递 · 02-26
Fractyl Health完成Revita®用于GLP-1治疗后体重维持的REMAIN-1关键队列随机分组
Fractyl Health, Inc.盘中异动 下午盘股价大涨5.30%
市场透视 · 02-19
Fractyl Health, Inc.盘中异动 下午盘股价大涨5.30%
Fractyl Health, Inc.盘中异动 快速下跌5.61%
市场透视 · 02-04
Fractyl Health, Inc.盘中异动 快速下跌5.61%
Fractyl Health, Inc.股价重挫66.81% 市值跌6222.88万美元
市场透视 · 01-29
Fractyl Health, Inc.股价重挫66.81% 市值跌6222.88万美元
Fractyl Health股价暴跌64%;公司公布停用减肥药后体重反弹的早期数据
美股速递 · 01-29
Fractyl Health股价暴跌64%;公司公布停用减肥药后体重反弹的早期数据
Fractyl Health 预计将于2026年第二季度获得FDA关于采用De Novo审批途径可能性的反馈
美股速递 · 01-29
Fractyl Health 预计将于2026年第二季度获得FDA关于采用De Novo审批途径可能性的反馈
Fractyl Health任命Lara Smith Weber为首席财务官,助力公司迈向商业化新阶段
美股速递 · 01-06
Fractyl Health任命Lara Smith Weber为首席财务官,助力公司迈向商业化新阶段
Fractyl Health, Inc.盘中异动 早盘股价大跌5.13%报2.13美元
市场透视 · 01-05
Fractyl Health, Inc.盘中异动 早盘股价大跌5.13%报2.13美元
Fractyl Health公布REMAIN-1关键队列6个月顶线数据,预计2026年下半年提交PMA申请
美股速递 · 01-05
Fractyl Health公布REMAIN-1关键队列6个月顶线数据,预计2026年下半年提交PMA申请
Fractyl Health, Inc.盘中异动 早盘股价大涨5.07%
市场透视 · 2025-12-29
Fractyl Health, Inc.盘中异动 早盘股价大涨5.07%
Fractyl Health: 2026年下半年预计将公布关键6个月的主要数据及潜在的PMA申请
美股速递 · 2025-12-02
Fractyl Health: 2026年下半年预计将公布关键6个月的主要数据及潜在的PMA申请
Fractyl Health公布积极的6个月Reveal-1开放标签结果 显示单次Revita®手术后持续的GLP-1体重维持
美股速递 · 2025-12-02
Fractyl Health公布积极的6个月Reveal-1开放标签结果 显示单次Revita®手术后持续的GLP-1体重维持
Fractyl Health 发布2025年第三季度业绩;Revita® 临床势头增强,向2026年关键结果及PMA申请迈进,现金流延续至2027年初
美股速递 · 2025-11-13
Fractyl Health 发布2025年第三季度业绩;Revita® 临床势头增强,向2026年关键结果及PMA申请迈进,现金流延续至2027年初
Fractyl Health宣布其肥胖症双GIP/GLP-1基因治疗候选药物Rjva-002获得强有力的临床前结果
美股速递 · 2025-10-07
Fractyl Health宣布其肥胖症双GIP/GLP-1基因治疗候选药物Rjva-002获得强有力的临床前结果
Fractyl Health, Inc.盘中异动 急速拉升5.16%报1.63美元
市场透视 · 2025-10-06
Fractyl Health, Inc.盘中异动 急速拉升5.16%报1.63美元
Fractyl Health, Inc.2024财年实现净利润-68.69百万美元,同比增加10.90%
市场透视 · 2025-03-09
Fractyl Health, Inc.2024财年实现净利润-68.69百万美元,同比增加10.90%
Fractyl Health, Inc.盘中异动 下午盘股价大涨5.00%
市场透视 · 2025-03-06
Fractyl Health, Inc.盘中异动 下午盘股价大涨5.00%
Fractyl Health(GUTS.US):2024年Q4财报实现营收3000美元,前值为7000美元,预期值为1万美元;每股收益为-0.52美元,前值为-11.18美元,预期值为-0.44美元。
金融界 · 2025-03-04
Fractyl Health(GUTS.US):2024年Q4财报实现营收3000美元,前值为7000美元,预期值为1万美元;每股收益为-0.52美元,前值为-11.18美元,预期值为-0.44美元。
Fractyl Health第四季度GAAP每股收益$(0.52)不及预期$(0.34),销售额$3.00K不及预期$10.00K
财报速递 · 2025-03-04
Fractyl Health第四季度GAAP每股收益$(0.52)不及预期$(0.34),销售额$3.00K不及预期$10.00K
加载更多
公司概况
公司名称:
Fractyl Health
所属市场:
NASDAQ
上市日期:
--
主营业务:
Fractyl Health, Inc.于2010年8月30日在特拉华州注册成立。该公司是一家临床阶段的代谢疗法公司,专注于开发治疗肥胖和2型糖尿病的新方法。其主要候选产品Revita DMR系统旨在重塑十二指肠黏膜,以解决代谢疾病的根本原因。
发行价格:
--
{"stockData":{"symbol":"GUTS","market":"US","secType":"STK","nameCN":"Fractyl Health","latestPrice":0.5087,"timestamp":1776196800000,"preClose":0.49,"halted":0,"volume":1676596,"hourTrading":{"tag":"盘后","latestPrice":0.51,"preClose":0.5087,"latestTime":"16:12 EDT","volume":313,"amount":159.23810522,"timestamp":1776197561147,"change":0.0013,"changeRate":0.002556,"amplitude":0.004914},"delay":0,"changeRate":0.03816326530612255,"floatShares":128000000,"shares":158648963,"eps":-1.86,"marketStatus":"盘后交易","change":0.0187,"latestTime":"04-14 16:14:49 EDT","open":0.4778,"high":0.5159,"low":0.4778,"amount":840335.63418264,"amplitude":0.077755,"askPrice":0.52,"askSize":1000,"bidPrice":0.4801,"bidSize":500,"shortable":3,"etf":0,"ttmEps":-1.86,"tradingStatus":3,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1776211200000},"marketStatusCode":4,"adr":0,"listingDate":1706850000000,"exchange":"NASDAQ","adjPreClose":0.49,"preHourTrading":{"tag":"盘前","latestPrice":0.4867,"preClose":0.49,"latestTime":"09:13 EDT","volume":5591,"amount":2637.7616761,"timestamp":1776172385470,"change":-0.0033,"changeRate":-0.006735,"amplitude":0.047347},"postHourTrading":{"tag":"盘后","latestPrice":0.51,"preClose":0.5087,"latestTime":"16:12 EDT","volume":313,"amount":159.23810522,"timestamp":1776197561147,"change":0.0013,"changeRate":0.002556,"amplitude":0.004914},"volumeRatio":1.624576},"requestUrl":"/m/hq/s/GUTS","defaultTab":"news","newsList":[{"id":"1170305837","title":"Fractyl Health将于2026年3月24日公布2025年第四季度及全年财务业绩并更新业务进展","url":"https://stock-news.laohu8.com/highlight/detail?id=1170305837","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1170305837?lang=zh_cn&edition=full","pubTime":"2026-03-17 19:01","pubTimestamp":1773745279,"startTime":"0","endTime":"0","summary":"Fractyl Health计划于2026年3月24日发布2025财年第四季度及全年财务报告,届时将同步披露公司最新业务动态。此次公告将全面展示企业在财务表现和战略推进方面的关键成果。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","GUTS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1142614142","title":"Fractyl Health完成Revita®用于GLP-1治疗后体重维持的REMAIN-1关键队列随机分组","url":"https://stock-news.laohu8.com/highlight/detail?id=1142614142","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1142614142?lang=zh_cn&edition=full","pubTime":"2026-02-26 20:03","pubTimestamp":1772107438,"startTime":"0","endTime":"0","summary":"Fractyl Health宣布,其针对GLP-1受体激动剂治疗后体重维持的Revita®疗法,已顺利完成REMAIN-1关键研究队列的随机化分组工作。这一里程碑标志着该创新代谢干预方案向临床验证迈出关键一步。\n随机化过程的完成,为评估Revita®在维持减肥效果方面的有效性与安全性奠定了坚实基础。研究结果有望为接受GLP-1治疗后面临体重反弹难题的患者提供全新解决方案。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GUTS","BK4082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2612298478","title":"Fractyl Health, Inc.盘中异动 下午盘股价大涨5.30%","url":"https://stock-news.laohu8.com/highlight/detail?id=2612298478","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2612298478?lang=zh_cn&edition=full","pubTime":"2026-02-19 04:12","pubTimestamp":1771445578,"startTime":"0","endTime":"0","summary":"北京时间2026年02月19日04时12分,Fractyl Health, Inc.股票出现异动,股价急速拉升5.30%。Fractyl Health, Inc.股票所在的生物技术行业中,整体跌幅为0.10%。其相关个股中,Sensei Biotherapeutics, Inc.、Cardio Diagnostics Holdings Inc.、Moolec Science Sa C/Wts 30/01/2028涨幅较大,Cardio Diagnostics Holdings Inc.、Moolec Science Sa、Sensei Biotherapeutics, Inc.较为活跃,换手率分别为2432.91%、953.51%、912.28%,振幅较大的相关个股有Moolec Science Sa C/Wts 30/01/2028、Cardio Diagnostics Holdings Inc.、Sensei Biotherapeutics, Inc.,振幅分别为160.33%、137.65%、108.11%。Fractyl Health, Inc.公司简介:Fractyl Health Inc 是一家代谢治疗公司,专注于开发治疗代谢疾病的新方法,包括2型糖尿病和肥胖症。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026021904125895416b98&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026021904125895416b98&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["GUTS","BK4082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2609739279","title":"Fractyl Health, Inc.盘中异动 快速下跌5.61%","url":"https://stock-news.laohu8.com/highlight/detail?id=2609739279","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609739279?lang=zh_cn&edition=full","pubTime":"2026-02-04 23:11","pubTimestamp":1770217876,"startTime":"0","endTime":"0","summary":"北京时间2026年02月04日23时11分,Fractyl Health, Inc.股票出现波动,股价急速下跌5.61%。Fractyl Health, Inc.股票所在的生物技术行业中,整体涨幅为0.59%。其相关个股中,Celularity Inc C/Wts 16/07/2026 、Neurosense Therapeutics Ltd C/Wts 10/11/2026 、阿诺医药涨幅较大,Biodexa Pharmaceuticals Plc、Gri Bio, Inc.、Evogene Ltd.较为活跃,换手率分别为380.93%、196.84%、116.84%,振幅较大的相关个股有Celularity Inc C/Wts 16/07/2026 、Nrx Pharmaceuticals Inc C/Wts 24/05/2026 、Liminatus Pharma, Inc.,振幅分别为61.25%、33.87%、33.64%。Fractyl Health, Inc.公司简介:Fractyl Health Inc 是一家代谢治疗公司,专注于开发治疗代谢疾病的新方法,包括2型糖尿病和肥胖症。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260204231117a47c6dd8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260204231117a47c6dd8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["GUTS","BK4082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2607039539","title":"Fractyl Health, Inc.股价重挫66.81% 市值跌6222.88万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2607039539","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607039539?lang=zh_cn&edition=full","pubTime":"2026-01-29 22:41","pubTimestamp":1769697686,"startTime":"0","endTime":"0","summary":"北京时间2026年01月29日22时41分,Fractyl Health, Inc.股票出现异动,股价快速跳水66.81%。Fractyl Health, Inc.股票所在的生物技术行业中,整体涨幅为0.24%。其相关个股中,Jasper Therapeutics Inc C/Wts 24/09/2026 、Briacell Therapeutics Corp C/Wts 、Serina Therapeutics, Inc.涨幅较大,Serina Therapeutics, Inc.、Aspire Biopharma Holdings, Inc.、Aprea Therapeutics, Inc.较为活跃,换手率分别为453.27%、103.55%、66.45%,振幅较大的相关个股有Biomx Inc.、Aprea Therapeutics, Inc.、Dermata Therapeutics, Inc.,振幅分别为31.00%、27.75%、21.83%。Fractyl Health, Inc.公司简介:Fractyl Health Inc 是一家代谢治疗公司,专注于开发治疗代谢疾病的新方法,包括2型糖尿病和肥胖症。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260129224126a4653e1a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260129224126a4653e1a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4082","GUTS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1102929804","title":"Fractyl Health股价暴跌64%;公司公布停用减肥药后体重反弹的早期数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1102929804","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1102929804?lang=zh_cn&edition=full","pubTime":"2026-01-29 22:34","pubTimestamp":1769697277,"startTime":"0","endTime":"0","summary":"Fractyl Health股价今日大幅下挫64%,创下近期最大单日跌幅。该公司同期发布了关于患者停止使用其肥胖症药物后出现体重反弹现象的初步研究数据。\n这份早期数据显示,在终止药物治疗后,部分患者的体重出现了显著回升。这一发现引发市场对该公司核心产品长期疗效可持续性的担忧,可能直接影响其未来商业化前景。\n股价的剧烈波动反映出投资者对该数据的负面解读,同时也凸显了肥胖症治疗领域药物研发存在的高风险特性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GUTS","BK4082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1171819577","title":"Fractyl Health 预计将于2026年第二季度获得FDA关于采用De Novo审批途径可能性的反馈","url":"https://stock-news.laohu8.com/highlight/detail?id=1171819577","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1171819577?lang=zh_cn&edition=full","pubTime":"2026-01-29 20:08","pubTimestamp":1769688510,"startTime":"0","endTime":"0","summary":"Fractyl Health Inc. 近日透露,公司预计将在2026年第二季度获得美国食品药品监督管理局(FDA)的关键反馈。此次沟通的核心议题是探讨其产品是否具备采用De Novo审批途径的资格。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GUTS","BK4082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1193253957","title":"Fractyl Health任命Lara Smith Weber为首席财务官,助力公司迈向商业化新阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=1193253957","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1193253957?lang=zh_cn&edition=full","pubTime":"2026-01-06 20:01","pubTimestamp":1767700876,"startTime":"0","endTime":"0","summary":"Fractyl Health宣布任命Lara Smith Weber担任公司首席财务官,这一关键人事布局旨在强化企业治理结构,为即将到来的商业化运营阶段做好充分准备。此次高管任命凸显了公司对财务战略规划与资本市场对接的高度重视,将有力推动其创新医疗技术的市场化进程。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","GUTS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2601922834","title":"Fractyl Health, Inc.盘中异动 早盘股价大跌5.13%报2.13美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2601922834","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601922834?lang=zh_cn&edition=full","pubTime":"2026-01-05 22:49","pubTimestamp":1767624586,"startTime":"0","endTime":"0","summary":"北京时间2026年01月05日22时49分,Fractyl Health, Inc.股票出现异动,股价大幅下跌5.13%。Fractyl Health, Inc.股票所在的生物技术行业中,整体跌幅为0.79%。其相关个股中,Abpro Holdings Inc C/Wts 12/11/2029 、Gh Research Plc、Altimmune, Inc.涨幅较大,Can Fite Biopharma Ltd、Psyence Biomedical Ltd.、Outlook Therapeutics, Inc.较为活跃,换手率分别为1243.75%、19.55%、16.51%,振幅较大的相关个股有Lexaria Bioscience Corp C/Wts 14/01/2026 、Jasper Therapeutics Inc C/Wts 24/09/2026 、Newcelx Ltd.,振幅分别为62.64%、27.42%、27.37%。Fractyl Health, Inc.公司简介:Fractyl Health Inc 是一家代谢治疗公司,专注于开发治疗代谢疾病的新方法,包括2型糖尿病和肥胖症。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260105224946953c0482&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260105224946953c0482&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4082","GUTS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1107730181","title":"Fractyl Health公布REMAIN-1关键队列6个月顶线数据,预计2026年下半年提交PMA申请","url":"https://stock-news.laohu8.com/highlight/detail?id=1107730181","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1107730181?lang=zh_cn&edition=full","pubTime":"2026-01-05 20:03","pubTimestamp":1767614595,"startTime":"0","endTime":"0","summary":"Fractyl Health公司宣布,其REMAIN-1研究关键队列的6个月顶线数据已公布。基于这些数据,公司预计将在2026年下半年提交潜在的上市前批准(PMA)申请。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GUTS","BK4082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2595768968","title":"Fractyl Health, Inc.盘中异动 早盘股价大涨5.07%","url":"https://stock-news.laohu8.com/highlight/detail?id=2595768968","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595768968?lang=zh_cn&edition=full","pubTime":"2025-12-29 22:43","pubTimestamp":1767019417,"startTime":"0","endTime":"0","summary":"北京时间2025年12月29日22时43分,Fractyl Health, Inc.股票出现波动,股价大幅拉升5.07%。Fractyl Health, Inc.股票所在的生物技术行业中,整体跌幅为0.10%。其相关个股中,Nrx Pharmaceuticals Inc C/Wts 24/05/2026 、Jasper Therapeutics Inc C/Wts 24/09/2026 、Nutriband Inc C/Wts 涨幅较大,Theriva Biologics, Inc.、Indaptus Therapeutics, Inc.、阿诺医药较为活跃,换手率分别为283.83%、242.38%、54.84%,振幅较大的相关个股有Psyence Biomedical Ltd C/Wts 25/01/2029、Nutriband Inc.、阿诺医药,振幅分别为55.30%、29.38%、27.44%。Fractyl Health, Inc.公司简介:Fractyl Health Inc 是一家代谢治疗公司,专注于开发治疗代谢疾病的新方法,包括2型糖尿病和肥胖症。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025122922433897a0cfda&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025122922433897a0cfda&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["GUTS","BK4082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1144969414","title":"Fractyl Health: 2026年下半年预计将公布关键6个月的主要数据及潜在的PMA申请","url":"https://stock-news.laohu8.com/highlight/detail?id=1144969414","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1144969414?lang=zh_cn&edition=full","pubTime":"2025-12-02 20:02","pubTimestamp":1764676931,"startTime":"0","endTime":"0","summary":"Fractyl Health: 2026年下半年预计将公布关键6个月的主要数据及潜在的PMA申请","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","GUTS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1160898506","title":"Fractyl Health公布积极的6个月Reveal-1开放标签结果 显示单次Revita®手术后持续的GLP-1体重维持","url":"https://stock-news.laohu8.com/highlight/detail?id=1160898506","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1160898506?lang=zh_cn&edition=full","pubTime":"2025-12-02 20:01","pubTimestamp":1764676861,"startTime":"0","endTime":"0","summary":"Fractyl Health公布积极的6个月Reveal-1开放标签结果,显示单次Revita®手术后,患者在接受GLP-1治疗后的体重维持情况显著。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GUTS","BK4082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1127463512","title":"Fractyl Health 发布2025年第三季度业绩;Revita® 临床势头增强,向2026年关键结果及PMA申请迈进,现金流延续至2027年初","url":"https://stock-news.laohu8.com/highlight/detail?id=1127463512","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1127463512?lang=zh_cn&edition=full","pubTime":"2025-11-13 05:06","pubTimestamp":1762981602,"startTime":"0","endTime":"0","summary":"Fractyl Health 发布2025年第三季度业绩;Revita® 临床势头增强,向2026年关键结果及PMA申请迈进,现金流延续至2027年初","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","GUTS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1190213535","title":"Fractyl Health宣布其肥胖症双GIP/GLP-1基因治疗候选药物Rjva-002获得强有力的临床前结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1190213535","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1190213535?lang=zh_cn&edition=full","pubTime":"2025-10-07 19:01","pubTimestamp":1759834893,"startTime":"0","endTime":"0","summary":"Fractyl Health宣布其肥胖症双GIP/GLP-1基因治疗候选药物Rjva-002获得强有力的临床前结果","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","GUTS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2573963430","title":"Fractyl Health, Inc.盘中异动 急速拉升5.16%报1.63美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2573963430","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2573963430?lang=zh_cn&edition=full","pubTime":"2025-10-06 22:36","pubTimestamp":1759761390,"startTime":"0","endTime":"0","summary":"北京时间2025年10月06日22时36分,Fractyl Health, Inc.股票出现异动,股价急速拉升5.16%。截至发稿,该股报1.63美元/股,成交量111.141万股,换手率0.84%,振幅7.10%。Fractyl Health, Inc.股票所在的生物技术行业中,整体跌幅为0.01%。Fractyl Health, Inc.公司简介:Fractyl Health Inc 是一家代谢治疗公司,专注于开发治疗代谢疾病的新方法,包括2型糖尿病和肥胖症。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025100622363194bce9b6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025100622363194bce9b6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4082","GUTS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2518400504","title":"Fractyl Health, Inc.2024财年实现净利润-68.69百万美元,同比增加10.90%","url":"https://stock-news.laohu8.com/highlight/detail?id=2518400504","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518400504?lang=zh_cn&edition=full","pubTime":"2025-03-09 00:01","pubTimestamp":1741449682,"startTime":"0","endTime":"0","summary":"3月9日,Fractyl Health, Inc.公布财报,公告显示公司2024财年净利润为-68.69百万美元,同比增加10.90%;其中营业收入为93000.00美元,同比减少22.50%,每股基本收益为-1.44美元。从资产负债表来看,Fractyl Health, Inc.总负债79.65百万美元,其中短期债务4.96百万美元,资产负债比为0.02,流动比率为3.63。机构评级:截至2025年3月9日,当前有2家机构对Fractyl Health, Inc.目标价做出预测,其中目标均价为8.00美元,其中最低目标价为6.00美元,最高目标价为10.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250309000252a266b42b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250309000252a266b42b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["GUTS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517926161","title":"Fractyl Health, Inc.盘中异动 下午盘股价大涨5.00%","url":"https://stock-news.laohu8.com/highlight/detail?id=2517926161","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517926161?lang=zh_cn&edition=full","pubTime":"2025-03-06 04:22","pubTimestamp":1741206128,"startTime":"0","endTime":"0","summary":"北京时间2025年03月06日04时22分,Fractyl Health, Inc.股票出现异动,股价急速上涨5.00%。Fractyl Health, Inc.股票所在的生物技术行业中,整体涨幅为1.86%。其相关个股中,Chimerix, Inc.、Geovax Labs Inc C/Wts 29/09/2025、Klotho Neurosciences Inc C/Wts 21/06/2029 涨幅较大,Silexion Therapeutics Corp、Tc Biopharm Plc、Bioxcel Therapeutics, Inc.较为活跃,换手率分别为973.32%、318.27%、313.68%,振幅较大的相关个股有Nkgen Biotech, Inc.、Klotho Neurosciences Inc C/Wts 21/06/2029 、Geovax Labs Inc C/Wts 29/09/2025,振幅分别为82.59%、54.27%、51.93%。Fractyl Health, Inc.公司简介:Fractyl Health Inc 是一家代谢治疗公司,专注于开发治疗代谢疾病的新方法,包括2型糖尿病和肥胖症。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306042208abea129d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306042208abea129d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["GUTS","BK4082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516669144","title":"Fractyl Health(GUTS.US):2024年Q4财报实现营收3000美元,前值为7000美元,预期值为1万美元;每股收益为-0.52美元,前值为-11.18美元,预期值为-0.44美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2516669144","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516669144?lang=zh_cn&edition=full","pubTime":"2025-03-04 05:29","pubTimestamp":1741037354,"startTime":"0","endTime":"0","summary":"Fractyl Health(GUTS.US):2024年Q4财报实现营收3000美元,前值为7000美元,预期值为1万美元;每股收益为-0.52美元,前值为-11.18美元,预期值为-0.44美元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/03/04052948499182.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["GUTS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1126943086","title":"Fractyl Health第四季度GAAP每股收益$(0.52)不及预期$(0.34),销售额$3.00K不及预期$10.00K","url":"https://stock-news.laohu8.com/highlight/detail?id=1126943086","media":"财报速递","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1126943086?lang=zh_cn&edition=full","pubTime":"2025-03-04 05:20","pubTimestamp":1741036842,"startTime":"0","endTime":"0","summary":"Fractyl Health 公布的季度每股亏损为$,低于分析师普遍预期的$,差异为52.94%。与去年同期$7.00千美元的销售额相比,这一数据下降了57.14%。以上内容来自Benzinga Earnings专栏,原文如下:$Fractyl Health$ reported quarterly losses of $ per share which missed the analyst consensus estimate of $ by 52.94 percent. This is a 95.35 percent increase over losses of $ per share from the same period last year. The company reported quarterly sales of $3.00 thousand which missed the analyst consensus estimate of $10.00 thousand by 70.00 percent. This is a 57.14 percent decrea","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Fractyl Health第四季度GAAP每股收益$(0.52)不及预期$(0.34),销售额$3.00K不及预期$10.00K","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GUTS"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://ir.fractyl.com","stockEarnings":[{"period":"1week","weight":0.0722},{"period":"1month","weight":0.0526},{"period":"3month","weight":-0.7562},{"period":"6month","weight":-0.6316},{"period":"1year","weight":-0.5149},{"period":"ytd","weight":-0.7773}],"compareEarnings":[{"period":"1week","weight":0.0412},{"period":"1month","weight":0.036},{"period":"3month","weight":-0.0111},{"period":"6month","weight":0.0315},{"period":"1year","weight":0.285},{"period":"ytd","weight":0.0061}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Fractyl Health, Inc.于2010年8月30日在特拉华州注册成立。该公司是一家临床阶段的代谢疗法公司,专注于开发治疗肥胖和2型糖尿病的新方法。其主要候选产品Revita DMR系统旨在重塑十二指肠黏膜,以解决代谢疾病的根本原因。","exchange":"NASDAQ","name":"Fractyl Health","nameEN":"Fractyl Health"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Fractyl Health(GUTS)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Fractyl Health(GUTS)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Fractyl Health,GUTS,Fractyl Health股票,Fractyl Health股票老虎,Fractyl Health股票老虎国际,Fractyl Health行情,Fractyl Health股票行情,Fractyl Health股价,Fractyl Health股市,Fractyl Health股票价格,Fractyl Health股票交易,Fractyl Health股票购买,Fractyl Health股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Fractyl Health(GUTS)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Fractyl Health(GUTS)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}